Incannex Healthcare reported that its oral combination therapy IHL-42X achieved statistically significant improvements in obstructive sleep apnoea during a Phase 2 trial that enrolled patients across placebo, low-dose and high-dose arms. The company said the high-dose cohort recorded maximum Apnoea-Hypopnoea Index reductions of up to 83%, while the low-dose group saw reductions of up to 79% versus baseline. Responder analysis showed 41.2 % of high-dose participants achieved at least a 30 % cut in AHI and 14.7 % exceeded a 50 % reduction, indicating a meaningful effect for a subset of patients. Exit interviews found 57.6 % of all subjects perceived their condition had improved, and 89.5 % of those described the change as meaningful, citing better sleep quality, less fatigue and improved daily functioning. The treatment was well tolerated, with no serious adverse events and mostly mild-to-moderate side effects. Incannex said the data, which also demonstrated preservation of REM sleep and improvements in oxygen desaturation and wake-after-sleep-onset, will guide the design of a Phase 3 programme as the company seeks an alternative to positive airway pressure therapy for a multi-billion-dollar OSA market.